Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.
History of Aptinyx
Aptinyx Inc. was spun out of a predecessor company, Naurex Inc., following the acquisition of Naurex by Allergan in 2015.
Allergan’s acquisition was focused on Naurex’s lead NMDA receptor modulators in clinical development as differentiated therapies for depression: Phase 3-ready rapastinel (formerly called GLYX-13) and Phase 2 drug candidate NRX-1074. Naurex had demonstrated that rapastinel and NRX-1074 had rapid-acting and robust antidepressant efficacy and were very well tolerated. The research and development of these lead compounds provided clear validation of Naurex’s unique mechanism for modulating the NMDA receptor.
Based on key attributes of rapastinel and NRX-1074, Naurex built an extensive chemistry platform for discovering small molecules that modulate the NMDA receptor, including many with varied activity and selectivity. Upon the acquisition by Allergan, the Naurex team spun out this platform and the resultant early-stage development programs into a new company, Aptinyx, with the goal of continuing the successful track record of innovation to develop meaningful advances in the treatment of additional diseases of the brain and central nervous system.